A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

South Korea

H Plus Yangji Hospital, Seoul